STOCK TITAN

Bio Essence estimates $1.2M need amid going-concern doubt

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Bio Essence Corp (BIOE) reported nine-month revenue of $1,548,268 and net income of $324,992 for the period ended September 30, 2026, compared with $418,112 in revenue and a $132,890 net loss a year earlier. Third-quarter revenue was $253,020; the company recorded a $150,458 net loss versus $12,998 net income in the prior-year quarter.

Operating activities used $721,168 in cash; cash was $201,511 and the working capital deficit was $1,374,178 at September 30. Management said the accumulated deficit and reliance on additional financing raise substantial doubt about the company’s ability to continue as a going concern, and estimated a need for $1,200,000 to fund current operations for the next 12 months. Disclosure controls and internal control over financial reporting were not effective.

Bio Essence issued 7,000,000 shares, valued at $3,500,000, to acquire MediFlow AI software. A separate agreement with Zhituo provides for $1,000,000 in cash and 10,000,000 common shares for software development; as of September 30, $500,000 had been paid, with the remaining cash tied to milestones. Shares are issuable only after all development obligations are completed and final written acceptance.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 4 points

How the balance works

Positive

  • Moderate pointNine-month revenue increased 270.3% to $1,548,268.
  • Moderate pointNine-month results shifted from a $132,890 loss to $324,992 income.

Negative

  • Major pointManagement cited substantial doubt alongside a $1,374,178 working capital deficit.
  • Moderate pointThird-quarter results shifted from $12,998 income to a $150,458 loss.
  • Moderate pointOperating activities used $721,168 in cash, versus $328,701 provided a year earlier.
  • Moderate pointDisclosure controls and internal control over financial reporting were not effective as of September 30, 2026.

Filing Explained

The Stason lease case seeks about $1.5 million and is in discovery; Bio Essence says it has accrued that amount. A separate Statement of Work claim remains under evaluation, with no loss accrued because management says a loss was neither probable nor estimable.

Nine-month revenue $1,548,268 Nine months ended September 30, 2026; $418,112 in the comparable 2025 period, a 270.3% increase.
Nine-month net income $324,992 Nine months ended September 30, 2026; compared with a $132,890 net loss in 2025.
Third-quarter net loss $150,458 Three months ended September 30, 2026; compared with $12,998 net income in 2025.
Net cash used in operating activities $721,168 used Nine months ended September 30, 2026; compared with $328,701 provided in 2025.
Working capital deficit $1,374,178 As of September 30, 2026.
Cash $201,511 As of September 30, 2026.
MediFlow AI acquisition consideration $3,500,000 Value of 7,000,000 common shares issued to acquire the software.
Development agreement shares 10,000,000 common shares Earned and issuable only after completion of all development obligations and written final acceptance.
going concern financial
"substantial doubt about the Company’s ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
working capital deficit financial
"working capital deficit of $1,374,178"
A working capital deficit occurs when a company's short-term obligations—like bills, supplier payments and near-term debt—are larger than its readily available short-term resources such as cash, money expected from customers, and inventory that can be sold. Like a household whose monthly bills exceed its checking account, it signals potential difficulty paying immediate expenses, which matters to investors because it raises the chance the company will need outside financing or cut operations, affecting risk and value.
retrieval-augmented generation technical
"retrieval-augmented generation platform integrated with MediFlow"
An AI method that combines a conversational language system with live access to external documents or databases, so the AI first fetches relevant facts and then uses them to form its answer. Think of it as an assistant that checks a file cabinet for source papers before replying, which helps reduce mistakes and reveal evidence. For investors it matters because it can produce more accurate, verifiable summaries of filings, news and research, speeding due diligence while still depending on the quality of the underlying data.
asset purchase agreement financial
"entered into an Asset Purchase Agreement with Zhituo"
An asset purchase agreement is a legal contract in which a buyer agrees to buy specific assets and contracts of a business rather than buying the company’s stock or ownership. It matters to investors because it determines exactly what is being bought and what liabilities stay behind — like buying the furniture and equipment from a store but not the building or past debts — which affects the deal’s value, taxes and future risk exposure.
operating lease liabilities financial
"operating lease liabilities (current and non-current)"
Long-term lease payments a company is legally committed to because it rents assets such as offices, factories, or equipment; under modern accounting rules these future rent obligations are recorded on the balance sheet as liabilities. Investors care because operating lease liabilities act like debt that drains future cash, affects measures of leverage and borrowing capacity, and can change profitability and valuation — think of them as a company’s large, ongoing rent payments that limit its financial flexibility.
current expected credit loss financial
"current expected credit loss (“CECL”) methodology"
An accounting approach that requires lenders and companies to estimate and record the credit losses they expect on loans and receivables now, using current conditions and reasonable forecasts rather than waiting for a default to occur. It matters to investors because it changes reported reserves and profits up front and gives an earlier, more forward-looking signal of credit quality—like packing an umbrella today because the forecast predicts rain, which affects a company’s cushion against bad loans.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue and net income did BIOE report for the first nine months of 2026?

Bio Essence reported $1,548,268 in revenue and $324,992 in net income for the nine months ended September 30, 2026. Revenue was $418,112 and the company reported a $132,890 net loss for the comparable 2025 period.

Did BIOE make a profit in the third quarter of 2026?

No. For the three months ended September 30, 2026, Bio Essence recorded a $150,458 net loss, compared with $12,998 net income for the third quarter of 2025.

What are the terms of BIOE’s MediFlow AI development agreement?

The agreement with Zhituo calls for $1,000,000 in cash and 10,000,000 common shares. As of September 30, 2026, Bio Essence had paid $500,000. The remaining cash is payable upon completion and acceptance of milestones, and the shares are earned only after all development obligations are completed and the company provides written final acceptance.

How much cash does Bio Essence estimate it needs for the next 12 months?

As of September 30, 2026, Bio Essence said it believed it would need $1,200,000 to continue its current business for the next 12 months. The company also said there is no assurance it can obtain additional funding on acceptable terms or at all.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
NONE 0001723059 false Q3 --12-31 1 0001723059 2026-07-01 2026-09-30 0001723059 us-gaap:SubsequentEventMember 2026-10-19 2026-10-19 0001723059 2026-01-01 2026-09-30 0001723059 2025-12-31 0001723059 2026-09-30 0001723059 2025-01-01 2025-12-31 0001723059 2026-03-09 2026-03-09 0001723059 bioe:SoftwareDevelopmentAgreementMember 2026-01-01 2026-09-30 0001723059 bioe:SoftwareDevelopmentAgreementMember 2026-09-30 0001723059 bioe:FinalAcceptanceMilestoneMember 2026-01-01 2026-09-30 0001723059 bioe:MilestoneThreeMember 2026-01-01 2026-09-30 0001723059 bioe:MilestoneTwoMember 2026-01-01 2026-09-30 0001723059 bioe:MilestoneOneMember 2026-01-01 2026-09-30 0001723059 bioe:SoftwareDevelopmentAgreementMember 2026-09-01 2026-09-01 0001723059 bioe:SoftwareDevelopmentAgreementMember 2026-09-01 0001723059 us-gaap:CommonStockMember bioe:TwoInvestorsMember 2026-09-21 2026-09-21 0001723059 us-gaap:CommonStockMember bioe:TwoInvestorsMember 2026-09-21 0001723059 us-gaap:CommonStockMember bioe:ZhituoSoftwareCoLimitedMember 2026-05-09 2026-05-09 0001723059 us-gaap:CommonStockMember bioe:ZhituoSoftwareCoLimitedMember 2026-05-09 0001723059 us-gaap:PrivatePlacementMember us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001723059 us-gaap:PrivatePlacementMember us-gaap:CommonStockMember 2026-09-30 0001723059 us-gaap:CommonStockMember 2025-12-31 0001723059 us-gaap:CommonStockMember 2026-09-30 0001723059 2025-09-30 0001723059 2025-07-01 2025-09-30 0001723059 2025-01-01 2025-09-30 0001723059 2026-07-01 2026-07-31 0001723059 2026-07-31 0001723059 2026-06-01 2026-06-01 0001723059 2025-03-03 0001723059 bioe:LandlordMember 2024-01-01 2024-12-31 0001723059 2024-01-01 2024-12-31 0001723059 2024-02-29 0001723059 2023-09-01 0001723059 2023-09-01 2023-09-01 0001723059 srt:WarehouseMember 2023-09-01 0001723059 2023-05-18 0001723059 bioe:GoldenCapitalAndWealthManagementLLCMember 2026-01-01 2026-09-30 0001723059 bioe:GoldenCapitalAndWealthManagementLLCMember 2026-05-18 0001723059 bioe:GovernmentLoansPayableMember 2026-01-01 2026-09-30 0001723059 bioe:GovernmentLoansPayableMember 2026-09-30 0001723059 2020-06-30 0001723059 2020-05-31 0001723059 bioe:EconomicInjuryDisasterLoanMember 2020-06-30 0001723059 bioe:EconomicInjuryDisasterLoanMember 2020-05-31 0001723059 us-gaap:SoftwarePurchasedMember 2026-05-07 0001723059 bioe:ZhituoMember 2026-05-07 2026-05-07 0001723059 2026-05-07 2026-05-07 0001723059 bioe:ZhituoMember 2026-05-07 0001723059 us-gaap:CommonStockMember bioe:ZhituoMember 2026-05-07 0001723059 us-gaap:TrademarksMember 2025-12-31 0001723059 us-gaap:TrademarksMember 2025-09-30 0001723059 us-gaap:SoftwareInDevelopmentMember 2025-12-31 0001723059 us-gaap:SoftwareInDevelopmentMember 2025-09-30 0001723059 us-gaap:SupplierConcentrationRiskMember bioe:PurchaseMember bioe:OneMajorVendorMember 2025-07-01 2025-09-30 0001723059 us-gaap:SupplierConcentrationRiskMember bioe:PurchaseMember bioe:TwoMajorVendorsMember 2025-01-01 2025-09-30 0001723059 us-gaap:SupplierConcentrationRiskMember bioe:PurchaseMember bioe:OneMajorVendorMember 2025-01-01 2025-09-30 0001723059 us-gaap:SupplierConcentrationRiskMember bioe:PurchaseMember bioe:OneMajorVendorMember 2026-07-01 2026-09-30 0001723059 us-gaap:SupplierConcentrationRiskMember bioe:PurchaseMember bioe:TwoMajorVendorsMember 2026-01-01 2026-09-30 0001723059 us-gaap:SupplierConcentrationRiskMember bioe:PurchaseMember bioe:OneMajorVendorMember 2026-01-01 2026-09-30 0001723059 us-gaap:CustomerConcentrationRiskMember bioe:TotalSalesMember bioe:FourMajorCustomerMember 2025-07-01 2025-09-30 0001723059 us-gaap:CustomerConcentrationRiskMember bioe:TotalSalesMember bioe:ThreeMajorCustomerMember 2025-07-01 2025-09-30 0001723059 us-gaap:CustomerConcentrationRiskMember bioe:TwoMajorCustomerMember bioe:TotalSalesMember 2025-07-01 2025-09-30 0001723059 us-gaap:CustomerConcentrationRiskMember bioe:OneMajorCustomerMember bioe:TotalSalesMember 2025-07-01 2025-09-30 0001723059 us-gaap:CustomerConcentrationRiskMember bioe:TotalSalesMember bioe:ThreeMajorCustomerMember 2025-01-01 2025-09-30 0001723059 us-gaap:CustomerConcentrationRiskMember bioe:TwoMajorCustomerMember bioe:TotalSalesMember 2025-01-01 2025-09-30 0001723059 us-gaap:CustomerConcentrationRiskMember bioe:OneMajorCustomerMember bioe:TotalSalesMember 2025-01-01 2025-09-30 0001723059 us-gaap:CustomerConcentrationRiskMember bioe:TotalSalesMember bioe:SixMajorCustomerMember 2026-07-01 2026-09-30 0001723059 us-gaap:CustomerConcentrationRiskMember bioe:TotalSalesMember bioe:FiveMajorCustomerMember 2026-07-01 2026-09-30 0001723059 us-gaap:CustomerConcentrationRiskMember bioe:TotalSalesMember bioe:FourMajorCustomerMember 2026-07-01 2026-09-30 0001723059 us-gaap:CustomerConcentrationRiskMember bioe:TotalSalesMember bioe:ThreeMajorCustomerMember 2026-07-01 2026-09-30 0001723059 us-gaap:CustomerConcentrationRiskMember bioe:TwoMajorCustomerMember bioe:TotalSalesMember 2026-07-01 2026-09-30 0001723059 us-gaap:CustomerConcentrationRiskMember bioe:OneMajorCustomerMember bioe:TotalSalesMember 2026-07-01 2026-09-30 0001723059 us-gaap:CustomerConcentrationRiskMember bioe:TwoMajorCustomerMember bioe:TotalSalesMember 2026-01-01 2026-09-30 0001723059 us-gaap:CustomerConcentrationRiskMember bioe:OneMajorCustomerMember bioe:TotalSalesMember 2026-01-01 2026-09-30 0001723059 bioe:BioEssenceHerbalEssentialsIncMember 2024-03-28 2024-03-28 0001723059 bioe:BioEssenceHerbalEssentialsIncMember 2024-03-28 0001723059 bioe:BioEssencePharmaceuticalIncMember 2023-12-12 2023-12-12 0001723059 bioe:BioEssencePharmaceuticalIncMember 2023-12-12 0001723059 2024-12-31 0001723059 us-gaap:RetainedEarningsMember 2025-09-30 0001723059 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001723059 us-gaap:CommonStockMember 2025-09-30 0001723059 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001723059 2025-06-30 0001723059 us-gaap:RetainedEarningsMember 2025-06-30 0001723059 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001723059 us-gaap:CommonStockMember 2025-06-30 0001723059 2025-04-01 2025-06-30 0001723059 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001723059 2025-03-31 0001723059 us-gaap:RetainedEarningsMember 2025-03-31 0001723059 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001723059 us-gaap:CommonStockMember 2025-03-31 0001723059 2025-01-01 2025-03-31 0001723059 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001723059 us-gaap:RetainedEarningsMember 2024-12-31 0001723059 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001723059 us-gaap:CommonStockMember 2024-12-31 0001723059 us-gaap:RetainedEarningsMember 2026-09-30 0001723059 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001723059 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001723059 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001723059 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001723059 2026-06-30 0001723059 us-gaap:RetainedEarningsMember 2026-06-30 0001723059 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001723059 us-gaap:CommonStockMember 2026-06-30 0001723059 2026-04-01 2026-06-30 0001723059 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001723059 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001723059 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001723059 2026-03-31 0001723059 us-gaap:RetainedEarningsMember 2026-03-31 0001723059 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001723059 us-gaap:CommonStockMember 2026-03-31 0001723059 2026-01-01 2026-03-31 0001723059 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001723059 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001723059 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001723059 us-gaap:RetainedEarningsMember 2025-12-31 0001723059 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001723059 bioe:CostOfGoodsManufactureMember 2025-07-01 2025-09-30 0001723059 bioe:CostOfGoodsManufactureMember 2026-07-01 2026-09-30 0001723059 bioe:CostOfGoodsManufactureMember 2025-01-01 2025-09-30 0001723059 bioe:CostOfGoodsManufactureMember 2026-01-01 2026-09-30 0001723059 bioe:ShippingAndDeliveryIncomeMember 2025-01-01 2025-09-30 0001723059 bioe:RevenueFromOEMServicesMember 2025-07-01 2025-09-30 0001723059 bioe:RevenueFromOEMServicesMember 2026-07-01 2026-09-30 0001723059 bioe:RevenueFromOEMServicesMember 2025-01-01 2025-09-30 0001723059 bioe:RevenueFromOEMServicesMember 2026-01-01 2026-09-30 0001723059 2026-11-12 0001723059 bioe:ShippingAndDeliveryIncomeMember 2026-01-01 2026-09-30 0001723059 bioe:ShippingAndDeliveryIncomeMember 2026-07-01 2026-09-30 0001723059 bioe:ShippingAndDeliveryIncomeMember 2025-07-01 2025-09-30 0001723059 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001723059 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001723059 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001723059 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001723059 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001723059 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 iso4217:USD iso4217:USD xbrli:shares xbrli:shares xbrli:pure bioe:Segments

 

 

U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


For the quarterly period ended September 30, 2026

 

OR

 

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number: 000-56263

 

 

 

BIO ESSENCE CORP.

(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)

 

California

(STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION)

 

94-3349551

(IRS EMPLOYEE IDENTIFICATION NO.)

 

2955 Main Street, Ste 202 Irvine, CA 92614

(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

 

888-816-1494

(ISSUER TELEPHONE NUMBER)

 

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

 

Yes ☒ No ☐

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☐ Smaller reporting company ☒
    Emerging Growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol   Name of Exchange on Which Registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of the latest practicable date, the Company has 53,809,000 shares of its common stock issued and outstanding.

 

 

 

 

 

 

TABLE OF CONTENTS

 

        PAGE
PART I   FINANCIAL INFORMATION   1
         
Item 1.   Financial Statements   1
    Balance Sheets as of June 30, 2026 (Unaudited) and December 31, 2025   1
    Statements of Operations for six months ended June 30, 2026 and 2025 (Unaudited)   2
    Statements of Changes in Stockholders’ Equity for six months ended June 30, 2026 and 2025 (Unaudited)   3
    Statements of Cash Flows for six months ended June 30, 2026 and 2025 (Unaudited)   4
    Notes to Financial Statements (Unaudited)   5
Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations   19
Item 3.   Quantitative and Qualitative Disclosures About Market Risk   27
Item 4.   Controls and Procedures   27
         
PART II   OTHER INFORMATION   28
         
Item 1.   Legal Proceedings   28
Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds   28
Item 3.   Defaults Upon Senior Securities   28
Item 4.   Mine Safety Disclosures   28
Item 5.   Other Information   28
Item 6.   Exhibits   28
    Signatures   29

 

i

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statement

 

BIO ESSENCE CORPORATION

BALANCE SHEETS

 

    As of
September 30,
2026 (Unaudited)
    As of
December 31,
2025
 
             
ASSETS            
             
Current Assets            
Cash   $ 201,511     $ -  
Accounts receivable     -       23,454  
Advance to vendors     -       10,000  
Prepaid expenses and other receivables     77,408       3,750  
Loan to shareholder     -       385,173  
Total Current Assets     278,919       422,377  
                 
Non-current Assets                
Prepayment for software development     500,000       -  
Intangible assets, net     3,221,438       97  
Total Non-current Assets     3,721,438       97  
                 
Total Assets   $ 4,000,357     $ 422,474  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)                
                 
Current Liabilities                
Bank overdraft   $ -     $ 1,531  
Accounts payable     -       47,879  
Customer deposit     123,236       848,601  
Accrued liabilities and other payables     12,359       35,854  
Taxes payable     4,667       -  
Operating lease liabilities - current     1,511,477       1,504,020  
Government loans payable - current     1,358       1,326  
Total Current Liabilities     1,653,097       2,439,211  
                 
Non-current Liabilities                
Government loans payable     55,161       56,156  
Total Non-current Liabilities     55,161       56,156  
                 
Total Liabilities     1,708,258       2,495,367  
                 
Commitment and contingencies                
                 
Stockholders’ Equity (Deficit)                
Preferred stock $0.0001 par value; authorized shares 10,000,000, no shares issued and outstanding as of September 30, 2026 and December 31, 2025     -       -  
Common stock $0.0001 par value; authorized shares 100,000,000; issued and outstanding shares 55,809,000 and 38,009,000 as of September 30, 2026 and December 31, 2025     5,581       3,801  
Additional Paid in capital     11,514,599       7,476,379  
Accumulated deficit     (9,228,081 )     (9,553,073 )
Total Stockholders’ Equity (Deficit)     2,292,099       (2,072,893 )
                 
Total Liabilities and Stockholders’ Equity (Deficit)   $ 4,000,357     $ 422,474  

 

The accompanying notes are an integral part of these financial statements

 

1

 

 

BIO ESSENCE CORPORATION

STATEMENTS OF OPERATIONS

(UNAUDITED)

 

    Nine Months ended
September 30,
    Three Months ended
September 30,
 
    2026     2025     2026     2025  
                         
Revenues                        
Revenue from OEM services   $ 1,548,268     $ 416,896     $ 253,020     $ 136,800  
Shipping and delivery Income     -       1,216       -       -  
Total revenues     1,548,268       418,112       253,020       136,800  
                                 
Cost of revenues                                
Cost of OEM services     619,493       133,120       113,859       41,040  
Total cost of revenues     619,493       133,120       113,859       41,040  
                                 
Gross profit     928,775       284,992       139,161       95,760  
                                 
Operating expenses                                
Selling     680       30,593       -       650  
General and administrative     592,135       384,015       298,286       80,857  
                                 
Total operating expenses     592,815       414,608       298,286       81,507  
                                 
Income (loss) from operations     335,960       (129,616 )     (159,125 )     14,253  
                                 
Other income (expenses)                                
Interest income (expense)     5,308       (1,646 )     3,508       (556 )
Other expenses     (1,193 )     (828 )     (8 )     (699 )
                                 
Other income (expenses), net     4,115       (2,474 )     3,500       (1,255 )
                                 
Income (loss) before income tax     340,075       (132,090 )     (155,625 )     12,998  
                                 
Income tax expense (benefit)     15,083       800       (5,167 )     -  
                                 
Net income (loss)   $ 324,992     $ (132,890 )   $ (150,458 )   $ 12,998  
                                 
Basic weighted average shares outstanding     49,987,755       38,009,000       54,026,391       38,009,000  
                                 
Basic and diluted net income (loss) per share   $ 0.01     $ (0.00 )   $ (0.00 )   $ 0.00  

 

The accompanying notes are an integral part of these financial statements

 

2

 

 

BIO ESSENCE CORPORATION

STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

                      Total  
          Additional           Stockholders’  
    Common Stock     Paid-in     Accumulated     Equity  
    Shares     Amount     Capital     Deficit     (Deficit)  
                               
Balance at January 1, 2026     38,009,000     $ 3,801     $ 7,476,379     $ (9,553,073 )   $ (2,072,893 )
                                         
Issuance of common stock for equity financing     8,800,000       880       439,120       -       440,000  
                                         
Net income for the period     -       -       -       205,373       205,373  
                                         
Balance at March 31, 2026     46,809,000       4,681       7,915,499       (9,347,700 )     (1,427,520 )
                                         
Issuance of common stock for acquisition of MediFlow AI software     7,000,000       700       3,499,300       -       3,500,000  
                                         
Net income for the period     -       -       -       270,077       270,077  
                                         
Balance at June 30, 2026     53,809,000       5,381       11,414,799       (9,077,623 )     2,342,557  
                                         
Issuance of common stock for equity financing     2,000,000       200       99,800       -       100,000  
                                         
Net loss for the period     -       -       -       (150,458 )     (150,458 )
                                         
Balance at September 30, 2026     55,809,000     $ 5,581     $ 11,514,599     $ (9,228,081 )   $ 2,292,099  

 

                      Total  
          Additional           Stockholders’  
    Common Stock     Paid-in     Accumulated     Equity  
    Shares     Amount     Capital     Deficit     (Deficit)  
Balance at January 1, 2025     38,009,000     $ 3,801     $ 7,476,379     $ (10,449,270 )   $ (2,969,090 )
                                         
Net loss for the period     -       -       -       (205,752 )     (205,752 )
                                         
Balance at March 31, 2025     38,009,000       3,801       7,476,379       (10,655,022 )     (3,174,842 )
                                         
Net income for the period     -       -       -       59,864       59,864  
                                         
Balance at June 30, 2025     38,009,000       3,801       7,476,379       (10,595,158 )     (3,114,978 )
                                         
Net income for the period     -       -       -       12,998       12,998  
                                         
Balance at September 30, 2025     38,009,000     $ 3,801     $ 7,476,379     $ (10,582,160 )   $ (3,101,980 )

 

The accompanying notes are an integral part of these financial statements

 

3

 

 

BIO ESSENCE CORPORATION

STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

    Nine Months Ended
September 30,
 
    2026     2025  
             
CASH FLOWS FROM OPERATING ACTIVITIES            
Net income (loss)   $ 324,992     $ (132,890 )
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:                
Depreciation and amortization expense     278,659       176  
Changes in assets/liabilities:                
Accounts receivable     23,454       155  
Prepaid expenses and other receivables     (73,658 )     187,796  
Prepayment and deposits     10,000       (64,265 )
Prepayment for software development     (500,000 )     -  
Accounts payable     (47,880 )     (7,131 )
Customer deposit     (725,365 )     642,524  
Tax payable     4,551       (316 )
Accrued liability and other payables     (23,378 )     (336,302 )
Other liability     -       4,208  
Operating lease liability     7,457       34,746  
Net cash provided by (used in) operating activities     (721,168 )     328,701  
                 
CASH FLOWS FROM INVESTING ACTIVITIES                
Repayment from shareholder     385,173       -  
Loan to related party     (500,000 )     -  
Repayment from related party     500,000       -  
Net cash provided by investing activities     385,173       -  
                 
CASH FLOWS FROM FINANCING ACTIVITIES                
Change in bank overdraft     (1,531 )     -  
Loan from shareholder     -       643,450  
Repayment to shareholder     -       (943,800 )
Repayment of SBA loan     (963 )     (981 )
Issuance of common stock     540,000       -  
Net cash provided by (used in) financing activities     537,506       (301,331 )
                 
NET INCREASE IN CASH     201,511       27,370  
                 
CASH AT THE BEGINNING OF PERIOD     -       1,371  
                 
CASH AT THE END OF PERIOD   $ 201,511     $ 28,741  
      -          
Supplemental Cash flow data:                
Cash paid for interest   $ 1,630     $ 1,646  
Cash paid for income taxes   $ 10,416     $ -  
                 
Non-Cash Investing Activities and Financing Activities                
Issuance of common stock to acquire intangible asset   $ 3,500,000     $ -  

 

The accompanying notes are an integral part of these financial statements

 

4

 

 

BIO ESSENCE CORPORATION

 

NOTES TO FINANCIAL STATEMENTS

 

SEPTEMBER 30, 2026 (UNAUDITED) AND DECEMBER 31, 2025

 

1. ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Bio Essence Corporation (“the Company” or “Bio Essence”) was incorporated in 2000 in the state of California. Bio Essence is mainly engaged in manufacturing and distributing health supplement products.

 

In January 2017, Bio Essence incorporated two subsidiaries in the state of California: Bio Essence Pharmaceutical Inc. (“BEP”) and Bio Essence Herbal Essentials, Inc. (“BEH”), Bio Essence transferred its manufacturing operation to BEP and transferred its distributing operation to BEH. On December 12, 2023, the Company entered into an agreement with Newways Inc. to sell the 100% equity ownership of BEP for $300,000. On March 28, 2024, the Company entered into an agreement with Health Up Inc. to sell the 100% equity ownership of BEH for $400,000.

 

Bio Essence incorporated a wholly owned subsidiary McBE Pharma Inc. (“McBE”) in the state of California, McBE will be engaged in developing, manufacturing and sales of prescription medicine. McBE has not engaged in any operations since its inception. On April 15, 2024, the Company dissolved McBE.

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These unaudited condensed financial statements should be read in conjunction with the Company’s audited financial statements and related notes included in its Annual Report on Form 10-K for the year ended December 31, 2025.

 

Going Concern

 

The Company incurred net income of $324,992 and net loss of $132,890 for the nine months ended September 30, 2026 and 2025, respectively. The Company also had an accumulated deficit of $9,228,081 and working capital deficit of $1,374,178 as of September 30, 2026. While the Company reported net income for the nine months ended September 30, 2026, management believes that the Company’s accumulated deficit and dependence on additional financing continue to raise substantial doubt about the Company’s ability to continue as a going concern. Management also intends to raise funds by way of a private or public offering, or by obtaining loans from banks or others. While the Company believes in the viability of its strategy to generate sufficient revenue and in its ability to raise additional funds on reasonable terms and conditions, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds by way of a public or private offering. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

5

 

 

Use of Estimates

 

In preparing financial statements in conformity with US GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.

 

Significant estimates, required by management, include the recoverability of long-lived assets, assumptions used in the accounting for leases, and the evaluation of contingencies. Actual results could differ from those estimates.

 

Leases

 

The Company follows ASC 842 and determines if an arrangement is a lease or contains a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, and operating lease liabilities (current and non-current) in the Company’s balance sheets. Finance leases are included in property and equipment, and finance lease liabilities (current and non-current) in the Company’s balance sheets.

 

ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the Company generally uses the incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

 

The Company elected the package of practical expedients permitted under the transition guidance to combine the lease and non-lease components as a single lease component for operating leases associated with the Company’s office space lease, and to keep leases with an initial term of 12 months or less off the balance sheet and recognize the associated lease payments in the statements of income on a straight-line basis over the lease term.

 

ROU assets are reviewed for impairment when indicators of impairment are present. ROU assets from operating and finance leases are subject to the impairment guidance in ASC 360, Property, Plant, and Equipment, as ROU assets are long-lived non-financial assets.

 

Cash and Cash Equivalents

 

For financial statement purposes, the Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

 

Credit Losses

 

On January1, 2023, the Company adopted Accounting Standards Update 2016-13 “Financial Instruments — Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments,” which replaces the incurred loss methodology with an expected loss methodology that is referred to as the current expected credit loss (“CECL”) methodology.

 

The Company’s account receivables and other receivables in the balance sheet are within the scope of ASC Topic 326. As the Company has limited customers and debtors, the Company uses the loss-rate method to evaluate the expected credit losses on an individual basis. When establishing the loss rate, the Company makes an assessment on various factors, including historical experience, credit-worthiness of customers and debtors, current economic conditions, reasonable and supportable forecasts of future economic conditions, and other factors that may affect its ability to collect from the customers and debtors. The Company also provides specific provisions for allowance when facts and circumstances indicate that the receivable is unlikely to be collected.

 

6

 

 

Expected credit losses are recognized as a provision for credit losses in the statements of operations, with a corresponding increase in the allowance for credit losses, which is presented as a reduction of the related receivables on the balance sheets. Receivables are written off against the allowance for credit losses when management determines that such amounts are uncollectible. Recoveries of amounts previously written off are recognized when received and reflected in the allowance for credit losses.

 

Accounts Receivable 

 

The Company’s policy is to maintain an allowance for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. As of September 30, 2026 and December 31, 2025, there was no allowance for credit loss.

 

Impairment of Long-Lived Assets

 

Long-lived assets, which include intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.

 

Recoverability of long-lived assets to be held and used is measured by comparing of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by it. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds its fair value (“FV”). FV is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Based on its review, the Company believes that, as of September 30, 2026 and December 31, 2025, there were no significant impairments of its long-lived assets.

 

Income Taxes

 

Income taxes are accounted for using an asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current period and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets also include the prior years’ net operating losses carried forward. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

 

The Company follows ASC Topic 740, which prescribes a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740 also provides guidance on recognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities, accounting for interest and penalties associated with tax positions, accounting for income taxes in interim periods, and income tax disclosures. 

 

7

 

 

Under the provisions of ASC Topic 740, when tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits is classified as interest expense and penalties are classified in selling, general and administrative expenses in the statement of income.

 

At September 30, 2026 and December 31, 2025, the Company did not take any uncertain positions that would necessitate recording a tax related liability. The Company files a U.S. income tax return. With few exceptions, the Company’s U.S. income tax return filed for the years ending on December 31, 2022 and thereafter are subject to examination by the relevant taxing authorities.

 

The Company accounts for income taxes in interim periods in accordance with FASB ASC 740-270, “Interim Reporting.” The Company has determined an estimated annual effective tax rate. The rate will be revised, if necessary, as of the end of each successive interim period during the Company’s fiscal year to its best current estimate. The estimated annual effective tax rate is applied to the year-to-date ordinary income (or loss) at the end of the interim period.

 

Revenue Recognition

 

The Company recognizes revenues following the five-step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.

 

Revenue is measured at the amount of consideration we expect to receive in exchange for the sale of our product, which occurs at a point in time, typically upon delivery to customers. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that it would have recognized is one year or less or the amount is immaterial.

 

Revenues from manufacture or OEM services are recognized when the manufacture process is completed pursuant to the customers’ requirements and the manufactured goods are delivered to the customers. 

 

Revenues from sales of goods are measured at net of reserves established for applicable discounts and allowances that are offered within contracts with the Company’s customers, and are recognized when the goods are delivered to customers.

 

Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, returns and rebates. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable as the amount is payable to the Company’s customers. 

 

The Company’s return policy allows for the return of damaged or defective products and shipment errors. A notice of damage or wrong items should be made within five days from receiving the goods, and actual return of the products must be completed within 30 days from the date of receiving the goods. Delayed notification for damaged or wrong products will not be accepted for return or exchange. Custom formulas and capsules are not returnable. The amounts for return of products were immaterial for the nine and three months ended September 30, 2026 and 2025.

 

8

 

 

Cost of Revenue

 

Cost of manufacture service/OEM consists primarily of direct labor costs and related overhead that are directly attributable to the manufacture process.

 

Shipping and Handling Costs

 

Shipping and handling costs related to delivery of finished goods are included in selling expenses. During the nine months ended September 30, 2026 and 2025, shipping and handling costs were $680 and $1,193. During the three months ended September 30, 2026 and 2025, shipping and handling costs were nil and 650, respectively.

 

Advertising

 

Advertising expenses consist primarily of costs of promotion and marketing for the Company’s image and products, and costs of direct advertising, and are included in selling expenses. The Company expenses all advertising costs as incurred. During the nine and three months ended September 30, 2026 and 2025, there were no advertising expenses incurred.

 

Fair Value (“FV”) of Financial Instruments

 

Certain of the Company’s financial instruments, including cash and equivalents, accrued liabilities and accounts payable, carrying amounts approximate their FV due to their short maturities. FASB ASC Topic 825, “Financial Instruments,” requires disclosure of the FV of financial instruments held by the Company. The carrying amounts reported in the balance sheets for current liabilities each qualify as financial instruments and are a reasonable estimate of their FV because of the short period of time between the origination of such instruments and their expected realization and the current market rate of interest.

 

Fair Value Measurements and Disclosures

 

ASC Topic 820, “Fair Value Measurements and Disclosures,” defines FV, and establishes a three-level valuation hierarchy for disclosures of FV measurement that enhances disclosure requirements for FV measures. The three levels are defined as follow:

 

● Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

 

● Level 3 inputs to the valuation methodology are unobservable and significant to the FV measurement.

 

As of September 30, 2026 and December 31, 2025, the Company did not identify any assets and liabilities that are required to be presented on the balance sheet at FV. The carrying value of cash, accounts receivable, loan to related party, loan to shareholders, accounts payable, taxes payable, other payables and accrued liabilities approximate estimated fair values because of their short maturities.

 

9

 

 

Earnings (Loss) per Share (EPS)

 

Basic EPS is computed by dividing net income by the weighted average number of common shares outstanding for the period. Diluted EPS is computed similar to basic net income per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if all the potential common shares pertaining to warrants, stock options, and similar instruments had been issued and if the additional common shares were dilutive. Diluted EPS are based on the assumption that all dilutive convertible shares and stock options and warrants were converted or exercised. Dilution is computed by applying the treasury stock method for the outstanding unvested restricted stock, options and warrants, and the if-converted method for the outstanding convertible instruments. Under the treasury stock method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later) and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Under the if-converted method, outstanding convertible instruments are assumed to be converted into common stock at the beginning of the period (or at the time of issuance, if later). There were no potentially dilutive securities outstanding (options and warrants) for the nine and three months ended September 30, 2026 and 2025.

 

Commitments and Contingencies

 

Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. As of September 30, 2026, the Company has potential legal contingencies described in Note 12.

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to credit risk consist primarily of accounts and other receivables. The Company does not require collateral or other security to support these receivables. The Company conducts periodic reviews of the financial condition and payment practices of its customers to minimize collection risk on accounts receivable.

 

For the nine months ended September 30, 2026, the Company had two major customers accounted for 38.7% and 16.2%, respectively of the Company’s total sales. For the three months ended September 30, 2026, the Company had six major customers accounted for 27.0%, 16.2%, 16.2%, 13.5%, 13.5%, and 13.5%, respectively of the Company’s total sales. For the nine months ended September 30, 2025, the Company had three major customers accounted for 45.6%, 16.4%, and 13.1%, respectively, of the Company’s total sales. For the three months ended September 30, 2025, the Company had four customers accounted for 40.0%, 20.0%, 20.0%, and 20.0%, respectively, of the Company’s total sales.

 

For the nine months ended September 30, 2026, the Company had two major vendors accounted for 56.1% and 42.9% of the Company’s total manufacturing service, respectively. For the three months ended September 30, 2026, the Company had one major vendor accounted for 100.0% of the Company’s total manufacturing service, respectively. For the nine months ended September 30, 2025, the Company had two major vendors accounted for 53.8% and 46.2% of the Company’s total manufacturing service, respectively. For the three months ended September 30, 2025, the Company had one major vendor accounted for 100.0% of the Company’s total manufacturing service, respectively.

 

10

 

 

Segment Reporting

 

ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s chief operating decision maker organizes segments within the Company for making operating decisions assessing performance and allocating resources. Reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company.

 

Management determined the Company’s operations constitute a single reportable segment in accordance with ASC 280. The Company operates exclusively in one business and industry segment: manufacture / OEM and sale of health supplement products.

 

New Accounting Pronouncements

 

In October 2023, the FASB issued ASU No. 2023-06, “Disclosure Improvements — Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative.” The ASU amends the disclosure or presentation requirements related to various subtopics in the FASB ASC. The ASU was issued in response to the SEC’s August 2018 final amendments in Release No. 33-10532, Disclosure Update and Simplification that updated and simplified disclosure requirements that the SEC believed were duplicative, overlapping, or outdated. The guidance in ASU 2023-06 is intended to align GAAP requirements with those of the SEC and to facilitate the application of GAAP for all entities. The amendments introduced by ASU 2023-06 are effective if the SEC removes the related disclosure or presentation requirement from its existing regulations by June 30, 2027. If, by June 30, 2027, the SEC has not removed the applicable requirements from its existing regulations, the pending content of the associated amendment will be removed from the ASC and will not become effective for any entities. Early adoption is permitted. The adoption of ASU 2023-06 is not expected to have a material impact on the Company’s financial statements or related disclosures.

 

On November 4, 2024, the FASB issued an ASU No. 2024-03, Disaggregation of Income Statement Expenses (“ASU 2024 03”) to improve the disclosures about a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses in commonly presented expense captions (such as cost of sales; selling, general, and administrative expenses; and research and development). The amendments in the ASU require disclosure in the notes to financial statements of specified information about certain costs and expenses. The amendments require that at each interim and annual reporting period an entity: 1.Disclose the amounts of (a) purchases of inventory, (b) employee compensation, (c) depreciation, (d) intangible asset amortization, and (e) depreciation, depletion, and amortization recognized as part of oil- and gas-producing activities (or other amounts of depletion expense) included in each relevant expense caption. A relevant expense caption is an expense caption presented on the face of the income statement within continuing operations that contains any of the expense categories listed in (a)–(e). 2. Include certain amounts that are already required to be disclosed under current generally accepted accounting principles in the same tabular disclosure as the other disaggregation requirements. 3. Disclose a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively. 4) Disclose the total amount of selling expenses and, in annual reporting periods, an entity’s definition of selling expenses.

 

In January 2025, the FASB issued ASU 2025-01 Income Statement-Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40). The FASB issued ASU 2024-03 on November 4, 2024-03 states that the amendments are effective for public business entities for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Following the issuance of ASU 2024-03, the FASB was asked to clarify the initial effective date for entities that do not have an annual reporting period that ends on December 31 (referred to as non-calendar year-end entities). Because of how the effective date guidance was written, a non-calendar year-end entity may have concluded that it would be required to initially adopt the disclosure requirements in ASU 2024-03 in an interim reporting period, rather than in annual reporting period. The FASB’s intent in the basis for conclusions of ASU 2024-03 is clear that all public business entities should initially adopt the disclosure requirements in the first annual reporting period beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact that the adoption of ASU 2025-01 will have on its financial statement presentation or disclosures.

 

11

 

 

In May 2025, the FASB issued ASU 2025-04, Compensation - Stock Compensation (Topic 18) and Revenue from contracts with Customers (Topic 606): Clarifications to Share-Based Consideration Payable to a Customer. The amendments provide guidance on identifying the accounting acquirer in transactions involving a variable interest entity. The amendments clarify the accounting for share-based consideration payable to a customer under Topic 718 and Topic 606. The amendments are effective for annual reporting periods, including interim reporting period within those annual periods, beginning after December 15, 2026. Early adoption is permitted. The Company is currently evaluating the impact of this amendment and does not expect that the adoption of this guidance will have a material impact on its financial position, results of operations, or cash flows.

 

In July 2025, the FASB issued ASU 2025-05, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. The amendments provide a practical expedient and, if applicable, an accounting policy election to simplify the measurement of credit losses for certain receivables and contract assets. The amendments are effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. Early adoption is permitted in any interim or annual period in which financial statements have not been issued or made available for issuance. Adoption did not affect the Company’s financial position or results of operations. 

 

The Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the Company’s financial position, statements of comprehensive income and cash flows.

 

3. ADVANCE TO VENDORS

 

Advance to vendors represents prepayments made to vendors for inventory purchases and related OEM services. As of September 30, 2026 and December 31, 2025, advance to vendors were nil and $10,000, respectively.

 

4. PREPAID EXPENSES AND OTHER RECEIVABLES

 

As of September 30, 2026 and December 31, 2025, prepaid expenses and other receivables were $77,408 and $3,750, respectively. As of September 30, 2026 and December 31, 2025, prepaid expenses and other receivables mainly consisted of prepaid professional fee and technical service fee.

 

5. PREPAYMENT FOR SOFTWARE DEVELOPMENT

 

On September 1, 2026, the Company entered into a technology development agreement with ZHITOU SOFTWARE CO., LIMITED (“Zhituo”) to develop a practitioner-facing artificial intelligence and retrieval-augmented generation platform as an integrated component of the Company’s MediFlow platform.

 

During the nine months ended September 30, 2026, the Company paid an initial advance of $500,000, representing 50% of the agreement’s total cash consideration of $1,000,000. As of September 30, 2026, the $500,000 was recorded as prepayment for software development. The agreement requires completion and delivery of the project by December 15, 2026, unless otherwise agreed in writing.

 

See Note 13, Commitments and Contingencies, for the remaining cash payment commitments and conditional equity consideration under the agreement.

 

12

 

 

6. INTANGIBLE ASSETS, NET

 

Intangible assets consisted of the following as of September 30, 2026 and December 31, 2025:

 

    September 30,
2026
    December 31,
2025
 
Computer Software   $ 3,536,928     $ 36,928  
Trademark     2,350       2,350  
Total     3,539,278       39,278  
Less: accumulated amortization     (317,840 )     (39,181 )
Net   $ 3,221,438     $ 97  

 

On April 20, 2026, the Company entered into an Asset Purchase Agreement (“APA”) with Zhituo Software Co., Limited, a company incorporated under the laws of Hong Kong (“Zhituo”). Under the APA, the Company acquired ownership of certain software known as MediFlow AI, along with all of its software source code, system architecture, data, APOs, frameworks, and other technical information and data, etc. (collectively the “Software”). On May 7, 2026, the Board of Directors approved to issue 7,000,000 shares of the Company’s common stock to Zhituo as the consideration for purchase the software. The total purchase consideration was fixed at $3,500,000, based on a fair market value of $0.50 per share, resulting in the issuance of 7,000,000 shares. The Company’s accounting policy is to commence amortization when software is available for use. The acquired Software is a finite-lived intangible asset with an estimated useful life of five years. Based on our review, the Software was substantially complete and available for its intended use as of May 7, 2026. Accordingly, amortization commenced on May 7, 2026 and is recognized on a straight-line basis over its estimated five-year useful life.

 

Amortization of intangible assets were $278,659 and $176 for the nine months ended September 30, 2026 and 2025, respectively.

 

Amortization of intangible assets were $175,000 and $59 for the three months ended September 30, 2026 and 2025, respectively.

 

Estimated amortization for the existing intangible assets with finite lives for each of the next five years at September 30, 2026 is as follows: $700,000, $700,000, $700,000, $700,000 and $421,439.

 

7. ACCRUED LIABILITIES AND OTHER PAYABLES

 

As of September 30, 2026, accrued liabilities and other payables consisted of payroll tax payable of $1,475.

 

As of December 31, 2025, accrued liabilities and other payables consisted of payroll tax payable of $1,591 and accrued expenses of $34,263.

 

8. GOVERNMENT LOANS PAYABLE

 

In May and June 2020, BEH, BEP and FDS received total of $215,600 from the Economic Injury Disaster Loan (“EIDL loan”) from the SBA after deducting $100 Uniform Commercial Code (“UCC”) handling charge and filing fee for each company. This is a low-interest federal disaster loan for working capital to small businesses and non-profit organizations of any size suffering substantial economic injury as a result of the Coronavirus (COVID-19), to help the businesses to meet financial obligations and operating expenses that could have been met had the disaster not occurred. This loan has interest of 3.75% and is not forgivable. The maturity of the loan is 30 years, installment payments including principal and interest of $288 monthly will begin 12 months from the date of the promissory note. On March 4, 2022, FDS transferred its EIDL loan to BEC due to the dissolution of FDS. The SBA extended the deferment period to allow small businesses and not-for-profits that received EIDL funds do not have to begin payments on the loan until 30 months after the date of the note. Accordingly, the company began to make installment payments in the fourth quarter 2022.

 

13

 

 

As of September 30, 2026, the future minimum EIDL loan payments to be paid by year are as follows:

 

Year Ending   Amount  
September 30, 2027   $ 1,358  
September 30, 2028     1,431  
September 30, 2029     1,484  
September 30, 2030     1,540  
September 30, 2031     1,598  
Thereafter     49,108  
Total   $ 56,519  

 

9. RELATED PARTY TRANSACTIONS

 

Loans to Shareholder

 

As of September 30, 2026, the Company had no loans to its major shareholders or officers.

 

As of December 31, 2025, the Company had loans to one major shareholder (also the Company’s senior officer) of $385,173. There are no written loan agreements for these loans, which are unsecured, non-interest bearing without fixed terms of repayment, and therefore, deemed receivable on demand. The loan was fully repaid in May 2026.

 

Loan to Related Party

 

On May 18, 2026, the Company provided a $500,000 loan to Golden Capital and Wealth Management, LLC, a Nevada limited liability company controlled by Yin Yan, the CEO of the Company. The loan bore a fixed annual interest rate of 5% and was due on June 30, 2027. The loan incurred interest income of $6,938.The loan was fully repaid by the related party in September 2026.

 

10. INCOME TAXES

 

The Company and its subsidiaries are subject to 21% federal corporate income tax in US.

 

At September 30, 2026 and December 31, 2025, the Company had net operating loss (“NOL”) for income tax purposes; for federal income tax purposes, the NOL arising in tax years beginning after 2017 may only offset 80% of a taxpayer’s taxable income, and may be carried forward indefinitely; for California income tax purposes, the entire NOL can be carried forward up to 20 years.

 

The Company has NOL carry-forwards for Federal and California income tax purposes of $3.47 million and $3.71 million at September 30, 2026 and December 31, 2025, respectively. No tax benefit was reported with respect to these NOL carry-forwards in the accompanying financial statements because the Company believes the realization of the Company’s net deferred tax assets for the NOL for both federal and California State of approximately $0.97 million as of September 30, 2026, was not considered more likely than not and accordingly, the potential tax benefits of the net loss carry-forwards are fully offset by a full valuation allowance.

 

14

 

 

Components of the Company’s deferred tax assets as of September 30, 2026 and December 31, 2025 are as follows:

 

    September 30,
2026
    December 31,
2025
 
Net deferred tax assets (liability):            
Depreciation and amortization expense   $ 2     $ 111  
Expected income tax benefit from NOL carry-forwards     970,567       1,037,704  
Less: valuation allowance     (970,569 )     (1,037,815 )
Deferred tax assets, net of valuation allowance   $ -     $ -  

 

Income Tax Provision in the Statements of Operations

 

A reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income taxes for the nine months ended September 30, 2026 and 2025 is as follows:

 

    2026     2025  
Federal statutory income tax expense (benefit) rate     21.00 %     (21.00 )%
State statutory income tax (benefit) rate, net of effect of state income tax deductible to federal income tax     6.98 %     (6.98 )%
Permanent difference     - %     - %
Change in valuation allowance     (23.55 )%     28.58 %
Effective income tax rate     4.44 %     0.60 %

 

A reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income taxes for three months ended September 30, 2026 and 2025 is as follows:

 

    2026     2025  
Federal statutory income tax expense (benefit) rate     (21.00 )%     21.00 %
State statutory income tax (benefit) rate, net of effect of state income tax deductible to federal income tax     (6.98 )%     6.98 %
Permanent difference     - %     - %
Change in valuation allowance     24.66 %     (27.98 )%
Effective income tax rate     (3.32 )%     0.00 %

 

The provision for income tax expense for the nine months ended September 30, 2026 and 2025 consisted of the following:

 

    2026     2025  
Current:            
Federal income tax expense   $ 14,283     $ -  
State income tax expense     800       800  
Deferred:                
Federal income tax expense     -       -  
State income tax expense     -       -  
Total income tax expense   $ 15,083     $ 800  

 

15

 

 

The provision for income tax expense for the three months ended September 30, 2026 and 2025 consisted of the following:

 

    2026     2025  
Current:            
Federal income tax benefit   $ (5,167 )   $       -  
State income tax expense     -       -  
Deferred:                
Federal income tax expense     -       -  
State income tax expense     -       -  
Total income tax expense   $ (5,167 )   $ -  

 

11. LEASES

 

Operating Leases

 

On May 18, 2023, the Company entered a 36-month lease with Stason Industrial Corporation for a facility including warehouse and office in the City of Irvine, California, with a security deposit of $50,000, effective on September 1, 2023. The monthly rent is approximately $47,100 with a 3% increase each year. On February 29, 2024 the Management moved out from the facilities and decided to seek early termination of this lease. The $50,000 security deposit was not returned to the Company and the negotiation of early termination is still ongoing as of the reporting date. During 2024, the Company recorded the full impairment of ROU asset of $1.05 million and kept $1.50 million lease liabilities associated with this lease in the Company’s financial statements due to uncertainty of the negotiation result with the landlord. The Company recently received a formal summons regarding a breach of contract lawsuit filed by the landlord. See Note 12– Commitments and Contingencies for further information regarding this litigation. 

 

On March 3, 2025, the Company entered a 12-month lease with THE PROPITIOUS IRVINE LLC for office space located in Irvine, California, commencing on June 1, 2025. The lease requires monthly rental payments of $3,000. The Company renewed the lease for an additional one-year term, commencing on June 1, 2026, with monthly rental payments of $3,000.

 

In July 2026, the Company entered into a 12-month office lease with Victory Property Partners LLC, with monthly base rent of $2,370 plus CAM fees of $1,749. The landlord verbally waived the July 2026 base rent.

 

The components of lease costs, lease term and discount rate with respect of warehouse and office lease with an initial term of more than 12 months are as follows:

 

    Nine Months
Ended
September 30,
2026
    Nine Months
Ended
September 30,
2025
 
Operating lease cost   $ 7,457     $ 34,746  
Weighted Average Remaining Lease Term - Operating leases including options to renew     -       -  
Weighted Average Discount Rate - Operating leases     5 %     5 %

 

    Three Months
Ended
September 30,
2026
    Three Months
Ended
September 30,
2025
 
Operating lease cost   $ 269     $ 9,400  
Weighted Average Remaining Lease Term - Operating leases including options to renew     -       -  
Weighted Average Discount Rate - Operating leases     5 %     5 %

 

16

 

 

12. STOCKHOLDERS’ EQUITY

 

Common Stock

 

The Company is authorized to issue 100,000,000 shares of common stock, par value $0.0001 per share. As of September 30, 2026 and December 31, 2025, there were 55,809,000 and 38,009,000 shares of common stock issued and outstanding, respectively.

 

During the nine months ended September 30, 2026, the Company issued an aggregate of 17,800,000 shares of common stock. Of these shares, 8,800,000 shares were issued at a purchase price of $0.05 per share in a private placement transaction for total gross proceeds of $440,000, which were used for general corporate purposes.

 

On May 7, 2026, the Board of Directors approved and on May 9, 2026, the Company issued 7,000,000 shares of common stock to Zhituo Software Co., Limited, or its designated assignees, in connection with the acquisition of MediFlow AI software and related assets pursuant to an Asset Purchase Agreement. The shares were valued at $0.50 per share, for an aggregate purchase price of $3,500,000.

 

On September 21, 2026, the Company issued an aggregate of 2,000,000 shares of common stock to two investors, with each investor purchasing 1,000,000 shares at a purchase price of $0.05 per share, for aggregate gross proceeds of $100,000.

 

13. COMMITMENT AND CONTINGENCIES

 

From time to time, the Company may be a party to various legal actions arising in the ordinary course of business. The Company accrues costs associated with these matters when they become probable and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.

 

Commitment

 

Software Development Agreement

 

On September 1, 2026, the Company entered into a technology development agreement with Zhituo for the development of a practitioner-facing artificial intelligence and retrieval-augmented generation platform integrated with MediFlow. The contractual consideration consists of $1,000,000 in cash and 10,000,000 shares of the Company’s common stock.

 

As of September 30, 2026, the Company had paid $500,000, which was recorded as prepayment for software development (see Note 5). The remaining cash consideration of $500,000 is payable upon completion and acceptance of specified development milestones: $200,000 for architecture, detailed specifications and the initial prototype; $200,000 for the retrieval-augmented generation engine and practitioner AI agent; $50,000 for MediFlow integration and administrative functionality; and $50,000 upon final acceptance. The respective target milestone dates are October 23, November 13, November 30 and December 15, 2026. The Company may withhold the applicable milestone payment until material acceptance issues are corrected.

 

The 10,000,000 shares of common stock are earned and issuable only upon completion of all development obligations, delivery of all required deliverables and the Company’s written final acceptance, subject to applicable corporate and securities-law requirements. No shares are earned or vested upon execution of the agreement or completion of an interim milestone. The agreement specifies a contractual price of $0.10 per share, or $1,000,000 in aggregate; this contractual amount does not necessarily represent the fair value of the equity consideration for financial reporting purposes.

 

17

 

 

The Company may terminate the agreement for convenience upon 15 days’ written notice. Upon such termination, the Company is obligated to pay only for accepted milestones and, if it elects to receive partially completed work, the reasonable documented value of usable work in progress approved by the Company, subject to delivery of that work and the associated source code. No shares are earned or payable if the agreement is terminated before final acceptance.

 

Contingencies 

 

On March 9, 2026, the Company was served with a summons and complaint filed by Stason Industrial Corporation (the “Plaintiff”). The complaint alleges breach of contract in connection with the Company’s early vacation of the Irvine facility and seeks damages of approximately $1.5 million.

 

As of December 31, 2025, the Company had accrued approximately $1.5 million related to this matter under lease liabilities. Management has evaluated the claim and determined that a loss is probable. While the Company intends to participate   in the legal process, management believes the $1.5 million operating lease liabilities recorded as of September 30, 2026 and December 31, 2025 represents the most likely outcome of this matter. Management does not believe it is reasonably possible that a loss materially in excess of the amount accrued will be incurred.

 

The complaint also asserts an additional cause of action alleging breach of a Statement of Work (“SOW”). The Plaintiff alleges that the Company failed to perform certain laboratory and pharmaceutical processing services and seeks recovery of alleged unreturned service payments as well as alleged lost revenues associated with a third-party agreement.

 

The Company is currently evaluating these allegations. The ultimate outcome of this claim is inherently uncertain, and management is presently unable to predict whether the Company will prevail. The Company intends to defend its position and may also engage in settlement discussions; however, the litigation remains in its early stages. As of September 30, 2026 and the reporting date, management concluded that a loss related to the SOW claim was neither probable nor reasonably estimable; accordingly, no accrual has been recorded for this matter. The Company has engaged legal counsel as of September 30, 2026 and the reporting date and filed its response to the complaint, and the litigation is in the discovery stage.

 

14. SUBSEQUENT EVENTS 

 

The Company follows the guidance in FASB ASC 855-10 for the disclosure of subsequent events. The Company evaluated subsequent events through the date the financial statements were issued and determined the Company has the following subsequent event need to be disclosed.

 

On October 19, 2026, the Company’s Board of Directors approved a proposed amendment to the Articles of Incorporation, subject to shareholder approval, to provide each outstanding share of preferred stock with 10,000 votes and each outstanding share of common stock with one vote on matters submitted to shareholders, except as otherwise required by applicable law or expressly provided in the amended Articles of Incorporation. On the same date, the Company’s shareholders approved an amendment to the Bylaws establishing an authorized board size of three to ten directors, unless otherwise approved by a majority of shareholders, and elected Xiying (Thea) Zhang and Geoff Fellows to the Board of Directors, effective October 19, 2026, increasing the number of serving directors from three to five.

 

18

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Business Overview

 

The Company was incorporated in 2000 in the state of California. Fusion Diet Systems (“FDS”) was incorporated in 2010 in the state of Utah. Bio Essence and FDS have been owned under common control since 2016. Bio Essence and FDS are mainly engaged in manufacturing and distributing health supplement products. In January 2017, Bio Essence incorporated two subsidiaries in the state of California: BEP and BEH, Bio Essence transferred its manufacturing operation into BEP and transferred its distributing operation into BEH. On March 1, 2017, the 100% shareholder of FDS transferred all her ownership in FDS into Bio Essence. On December 7, 2021, the Company dissolved FDS. On November 12, 2021, Bio Essence incorporated a wholly owned subsidiary McBE Pharma Inc. (“McBE”) in the state of California, McBE will be engaged in research and development and manufacture of prescription medicine. As a result of the ownership restructure, BEP, BEH, and MCBE became wholly owned subsidiaries of Bio Essence, and Bio Essence serves as a holding corporation for these subsidiaries. McBE has not engaged in any operations since its inception. On December 12, 2023, the Company entered into an agreement with Newway Inc. to sell the 100% equity ownership of BEP for $300,000. On March 28, 2024, the Company entered into an agreement with Health Up Inc to sell the 100% equity ownership of BEH for $400,000. On April 15, 2024, the Company dissolved McBE. 

 

The Company is mainly engaged in selling health supplements and providing OEM services. However, the Company currently outsources manufacture / OEM service after disposal of BEP in December 2023.

 

Related Party Transactions

 

Loan to Related Party

 

The Company provided a $500,000 loan to Golden Capital and Wealth Management, LLC, a Nevada limited liability company controlled by Yin Yan, the CEO of the Company, on May 18, 2026. The loan bears a fixed annual interest rate of 5% and is due on June 30, 2027. The loan was fully repaid in September 2026.

 

Critical Accounting Policies and Estimates 

 

Our management’s discussion and analysis of our financial condition and results of operations are based on our financial statements (“FS”), which were prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported net sales and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and assumptions. We base our estimates on historical experience and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. 

 

While our significant accounting policies are more fully described in Note 2 to our FS, we believe the following accounting policies are the most critical to assist you in fully understanding and evaluating this management discussion and analysis.

 

Basis of Presentation

 

The accompanying financial statements (“FS”) are prepared in conformity with U.S. Generally Accepted Accounting Principles (“US GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”). The functional currency of Bio Essence is U.S. dollars (“$’’). The accompanying financial statements are presented in U.S. dollars (“$”).

 

19

 

 

Going Concern

 

The Company incurred a net income of $324,992 and a net loss of $132,890 for the nine months ended September 30, 2026 and 2025, respectively. The Company incurred a net loss of $150,458 and a net income $12,998 for the three months ended September 30, 2026 and 2025, respectively. The Company also had an accumulated deficit of $9,228,081 as of September 30, 2026. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company plans to increase its income by strengthening its sales force, providing attractive sales incentive programs, and increasing marketing and promotion activities. Management also intends to raise additional funds by way of a private or public offering, or by obtaining loans from banks or others. While the Company believes in the viability of its strategy to generate sufficient revenue and in its ability to raise additional funds on reasonable terms and conditions, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds by way of a public or private offering. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Use of Estimates

 

In preparing financial statements in conformity with US GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.

 

Significant estimates, required by management, include the recoverability of long-lived assets, assumptions used in the accounting for leases, valuation of assets acquired in asset acquisition and the evaluation of contingencies. Actual results could differ from those estimates.

 

Credit Losses

 

On January1, 2023, the Company adopted Accounting Standards Update 2016-13 “Financial Instruments — Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments,” which replaces the incurred loss methodology with an expected loss methodology that is referred to as the current expected credit loss (“CECL”) methodology. 

 

The Company’s account receivables and other receivables in the balance sheet are within the scope of ASC Topic 326. As the Company has limited customers and debtors, the Company uses the loss-rate method to evaluates the expected credit losses on an individual basis. When establishing the loss rate, the Company makes the assessment on various factors, including historical experience, credit-worthiness of customers and debtors, current economic conditions, reasonable and supportable forecasts of future economic conditions, and other factors that may affect its ability to collect from the customers and debtors. The Company also provides specific provisions for allowance when facts and circumstances indicate that the receivable is unlikely to be collected.

 

Expected credit losses are recorded as allowance for credit losses on the statements of operations. After all attempts to collect a receivable have failed, the receivable is written off against the allowance. In the event the Company recovers amount that is previously reserved for, the Company will reduce the specific allowance for credit losses.

 

Accounts Receivable, Net

 

The Company’s policy is to maintain an allowance for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. As of September 30, 2026 and December 31, 2025, there was no bad debt allowance.

 

20

 

 

Revenue Recognition

 

The Company recognizes revenues following the five-step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.

 

Revenue is measured at the amount of consideration we expect to receive in exchange for the sale of our product, which occurs at a point in time, typically upon delivery to the customer. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that it would have recognized is one year or less or the amount is immaterial.

 

Revenues from sales of goods are measured at net of reserves established for applicable discounts and allowances that are offered within contracts with the Company’s customers, and are recognized when the goods are delivered to the customers.

 

Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, returns and rebates. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable as the amount is payable to the Company’s customers.

 

Revenues from manufacture services are recognized when the manufacture process is completed pursuant to the customers’ requirement and the finished goods were delivered to the customers.

 

The Company’s return policy allows for the return of damaged or defective products and shipment errors. A notice of damage or wrong items should make within five days from receiving the goods, and actual return of the products must be completed within 30 days from the date of receiving the goods. Delayed notification for damaged or wrong products will not be accepted for return or exchange. Custom formulas and capsules are not returnable. The amount for return of products was immaterial for the nine and three months ended September 30, 2026 and 2025.

 

Results of operations

 

Comparison for the nine months ended September 30, 2026 and 2025

 

The following table sets forth the results of our operations for the periods indicated as a percentage of net sales. Certain columns may not add due to rounding.

 

    2026     % of
sales
    2025     % of
sales
    Dollar
Increase
(Decrease)
    Percent
Increase
(Decrease)
 
Manufacture service revenue   $ 1,548,268       100.0 %   $ 416,896       99.7 %   $ 1,131,372       271.4 %
Shipping and delivery income     -       - %     1,216       0.3 %     (1,216 )     (100.0 )%
Total revenues     1,548,268       100.0 %     418,112       100.0 %     1,130,156       270.3 %
Cost of manufacture service     619,493       40.0 %     133,120       31.8 %     486,373       365.4 %
Total cost of revenues     619,493       40.0 %     133,120       31.8 %     486,373       365.4 %
Gross profit     928,775       60.0 %     284,992       68.2 %     643,783       225.9 %
Selling expenses     680       0.04 %     30,593       7.3 %     (29,913 )     (97.8 )%
General and administrative expenses     592,135       38.2 %     384,015       91.8 %     208,120       54.2 %
Operating expenses     592,815       38.3 %     414,608       99.2 %     178,207       43.0 %
Income (loss) from operations     335,960       21.7 %     (129,616 )     (31.0 )%     465,576       (359.2 )%
Other income (expenses), net     4,115       0.3 %     (2,474 )     (0.6 )%     6,589       (266.3 )%
Income (loss) before income taxes     340,075       22.0 %     (132,090 )     (31.6 )%     472,165       (357.5 )%
Income tax expense     15,083       1.0 %     800       0.2 %     14,283       1785.4 %
Net income (loss)   $ 324,992       21.0 %   $ (132,890 )     (31.8 )%   $ 457,882       (344.6 )%

 

21

 

 

Revenues

 

Revenues for the nine months ended September 30, 2026 and 2025 were $1,548,268 and $418,112, respectively. We had $1,548,268 OEM service revenue, and nil shipping and delivery income for the nine months ended September 30, 2026. We had $416,896 OEM service revenue, and $1,216 shipping and delivery income for the nine months ended September 30, 2025. The significant increase in revenue during the nine months ended September 30, 2026, compared to the same period in 2025, was primarily attributable to a higher volume of OEM service orders, including large orders from two new major customers. The Company’s strategic emphasis on OEM service revenue rather than product sales contributed to the overall growth in revenue and an improvement in the revenues.

 

Costs of revenues

 

Costs of revenues were $619,493 and $133,120 for the nine months ended September 30, 2026 and 2025, respectively. The increase was primarily due to the higher volume of OEM service orders during the period.

 

Gross profit

 

For the factors mentioned above, the gross profits  for the nine months ended September 30, 2026 and 2025 were $928,775 and $284,992, respectively. The increase in gross profit was mainly due to increase in revenues.

 

Operating expenses

 

Selling expenses consisted mainly of advertising, show expenses, products marketing, shipping expenses, and promotion expenses. Selling expenses for the nine months ended September 30, 2026 and 2025 were $680 and $30,593, respectively.

 

General and administrative expenses consisted mainly of employee salaries and welfare, business meeting, utilities, accounting, consulting, and legal expenses. General and administrative expenses were $592,135 for the nine months ended September 30, 2026, compared to $384,015 for the nine months ended September 30, 2025, an increase of $208,120 or 54.2%, the increase was mainly due to increased professional fee by $25,701, increased legal services fee by $17,277 and increased amortization expense from newly-acquired intangible assets by $278,483, which was partly offset by decreased office rent by $26,549, decreased salary by $27,465, decreased consulting fee by $43,227, decreased accounting fee by $14,020 and decreased dues and subscriptions expense by $4,367.

 

Other income (expenses), net

 

Other income was $4,115 and other expense was $2,474 for the nine months ended September 30, 2026 and 2025, respectively. For the nine months ended September 30, 2026, other income mainly consisted of interest income of $6,938, which was partly offset by interest expense of $1,630 and other expenses of $1,193. For the nine months ended September 30, 2025, other expenses mainly consisted of interest expense of $1,646 and other expenses of $828.

 

Net income (loss)

 

We had a net income of $324,992 for the nine months ended September 30, 2026, compared to a net loss $132,890 for the nine months ended September 30, 2025, an increase of $457,882 or 344.6%. The increase in revenue was mainly due to increased gross profit as described above.

 

22

 

 

Comparison for the three months ended September 30, 2026 and 2025

 

The following table sets forth the results of our operations for the periods indicated as a percentage of net sales. Certain columns may not add due to rounding.

 

    2026     % of
sales
    2025     % of
sales
    Dollar
Increase
(Decrease)
    Percent
Increase
(Decrease)
 
Manufacture service revenue   $ 253,020       100.0 %   $ 136,800       100.0 %   $ 116,220       85.0 %
Shipping and delivery income     -       - %     -       - %     -       - %
Total revenues     253,020       100.0 %     136,800       100.0 %     116,220       85.0 %
Cost of manufacture service     113,859       45.0 %     41,040       30.0 %     72,819       177.4 %
Total cost of revenues     113,859       45.0 %     41,040       30.0 %     72,819       177.4 %
Gross profit     139,161       55.0 %     95,760       70.0 %     43,401       45.3 %
Selling expenses     -       - %     650       0.5 %     (650 )     (100.0 )%
General and administrative expenses     298,286       117.9 %     80,857       59.1 %     217,429       268.9 %
Operating expenses     298,286       117.9 %     81,507       59.6 %     216,779       266.0 %
Income (loss) from operations     (159,125 )     (62.9 )%     14,253       10.4 %     (173,378 )     (1,216.4 )%
Other income (expenses), net     3,500       1.4 %     (1,255 )     (0.9 )%     4,755       (378.9 )%
Loss before income taxes     (155,625 )     (61.5 )%     12,998       9.5 %     (168,623 )     (1,297.3 )%
Income tax benefit     (5,167 )     (2.0 )%     -       - %     (5,167 )     (100.0 )%
Net income (loss)   $ (150,458 )     (59.5 )%   $ 12,998       9.5 %   $ (163,456 )     (1,257.5 )%

 

Revenues

 

Revenues for the three months ended September 30, 2026 and 2025 were $253,020 and $136,800, respectively. We had $253,020 OEM service revenue, and nil shipping and delivery income for the three months ended September 30, 2026. We had $136,800 OEM service revenue, and nil shipping and delivery income for the three months ended September 30, 2025. The significant increase in revenue during the three months ended September 30, 2026, compared to the same period in 2025, was primarily attributable to a higher volume of OEM service orders, including an increase in the number of major customers from four in the same period in 2025 to six in the current period. The Company’s strategic emphasis on OEM service revenue rather than product sales contributed to the overall growth in revenue and an improvement in the revenues.

 

Costs of revenues 

 

Costs of revenues for the three months ended September 30, 2026 and 2025 were $113,859 and $41,040, respectively. We had $113,859 and $41,040 cost for OEM service revenue for the three months ended September 30, 2026 and 2025. The increase in cost of revenues was mainly due to increase in revenues.

 

Gross profit

 

For the factors mentioned above, the gross profits  for the three months ended September 30, 2026 and 2025 were $139,161 and $95,760, respectively. The increase in gross profit was mainly due to increase in revenues.

 

Operating expenses

 

Selling expenses consisted mainly of advertising, show expenses, products marketing, shipping expenses, and promotion expenses. Selling expenses for the three months ended September 30, 2026 and 2025 were nil and $650, respectively.

 

General and administrative expenses consisted mainly of employee salaries and welfare, business meeting, utilities, accounting, consulting, and legal expenses. General and administrative expenses were $298,286 for the three months ended September 30, 2026, compared to $80,857 for the three months ended September 30, 2025, an increase of $217,429 or 268.9%, the increase was mainly due to increased amortization expense of newly-acquired intangible assets by $174,942, increased legal services by $8,737, increased professional fee by $3,042, and increased consulting fee by 53,875, which was partly offset by decreased salary expense by $13,531, and decreased office rent by 13,391.

 

Other income (expenses), net

 

Other income was $3,500 and other expense was $1,255 for the three months ended September 30, 2026 and 2025, respectively. For the three months ended September 30, 2026, other income mainly consisted of interest income of $4,056, which was partly offset by interest expense of $548 and other expenses of $8. For the three months ended September 30, 2025, other expenses mainly consisted of interest expense of $556 and other expenses of $699.

 

23

 

 

Net income (loss) 

 

We had a net loss of $150,458 for the three months ended September 30, 2026, compared to $12,998 for the three months ended September 30, 2025, a decrease of net income by $163,456 or 1,257.5%. The decrease in net income was mainly due to increased general and administrative expenses as described above.

 

Liquidity and Capital Resources

 

As of September 30, 2026, we had cash and equivalents of $201,511, other current assets of $77,408, other current liabilities of $1,653,097, working capital deficit of $1,374,178, a current ratio of 0.17:1. As of December 31, 2025,  we had no cash and equivalents, other current assets of $422,377, other current liabilities of $2,439,211, working capital deficit of $2,016,834, a current ratio of 0.17:1. 

 

The following is a summary of cash provided by or used in each of the indicated types of activities during the nine months ended September 30, 2026, and 2025, respectively.

 

    2026     2025  
Net cash provided by (used in) operating activities   $ (721,168 )   $ 328,701  
Net cash provided by (used in) investing activities   $ 385,173     $ -  
Net cash provided by (used in) financing activities   $ 537,506     $ (301,331 )

 

Net cash used in operating activities

 

Net cash used in operating activities was $721,168 for the nine months ended September 30, 2026, compared to net cash provided by operating activities of $328,701 for the nine months ended September 30, 2025. The increase of cash outflow of $1,049,869 from operating activities for the nine months ended September 30, 2026 was principally attributable to decreased non-cash activities adjustment from operating lease expense by $27,289, decreased cash inflow by $261,454 from prepaid expenses and other receivables, decreased cash inflow from customer deposits by $1,367,889, increased cash outflow from advance for software development by $500,000, increased cash outflow from accounts payable by $40,749, and decreased cash inflow from other current liability by $4,208, partly offset by increased net income by $457,882, increased non-cash activities adjustment from depreciation and amortization expense by $278,483, increased cash inflow from accounts receivable by $23,299, decreased cash outflow from prepayments and deposit by $74,265, decreased cash outflow from accrued liability and other payables by $312,924, and increased cash inflow from tax payable by $4,867.

 

Net cash used in investing activities

 

Net cash provided by investing activities was $385,173 for the nine months ended September 30, 2026, compared to net cash used in investing activities of nil for the nine months ended September 30, 2025. The increase of cash inflow of $385,173 from investing activities for the nine months ended September 30, 2026 mainly consisted of loan to related party of $500,000, repayment from related party of $500,000, and repayment from shareholder of $385,173.

 

Net cash provided by financing activities 

 

Net cash provided by financing activities was $537,506 for the nine months ended September 30, 2026, compared to net cash used in financing activities of $301,331 for the nine months ended September 30, 2025. The net cash provided by financing activities for the nine months ended September 30, 2026 mainly consisted issuance of common stock for the proceeds of $540,000 through two equity financing, partly offset by payment of government loan of $963, and decreased bank overdraft of $1,531.The net cash used in financing activities for the nine months ended September 30, 2025 mainly consisted of $943,800 loan repayment to one major shareholder (also the senior officer) and payment of government loan of $981, partly offset by proceeds of $643,450 loan from one major shareholder (also the senior officer).

 

24

 

 

Our current liabilities exceed current assets at September 30, 2026, however, we incurred a net income of $324,992 during the nine months ended September 30, 2026. We may have difficulty meeting upcoming cash requirements. As of September 30, 2026, we believe we will need $1.2 million cash to continue our current business for the next 12 months. In addition to our continuous effort to improve our sales and net profits, we have explored and continue to explore other options to provide additional financing to fund future operations as well as other possible courses of action. Such actions may include, but are not limited to, securing lines of credit, sales of debt or equity securities (which may result in dilution to existing shareholders), loans and cash advances from other third parties or banks, and other similar actions. There can be no assurance that we will be able to obtain additional funding (if needed), on acceptable terms or at all, through a sale of our common stock, loans from financial institutions, or other third parties, or any of the actions discussed above. If we cannot sustain profitable operations, and additional capital is unavailable, lack of liquidity could have a material adverse effect on our business viability, financial position, results of operations and cash flows.

 

On April 20, 2026, the Company entered into an Asset Purchase Agreement (“APA”) with Zhituo Software Co., Limited, a company incorporated under the laws of Hong Kong (“Zhituo”). Under the APA, the Company acquired ownership of certain software known as MediFlow AI, along with all of its software source code, system architecture, data, APOs, frameworks, and other technical information and data, etc. (collectively the “Software”). On May 7, 2026, the Board of Directors approved to issue 7,000,000 shares of the Company’s common stock to Zhituo as the consideration for purchase the software. The fair market value of 7,000,000 shares was $3,500,000

 

Contractual Obligations

 

Long-Term Debts

 

Government Loans

 

In May and June 2020, BEH, BEP and FDS received total of $215,600 from the Economic Injury Disaster Loan (“EIDL loan”) from the SBA after deducting $100 Uniform Commercial Code (“UCC”) handling charge and filing fee for each company. This is a low-interest federal disaster loan for working capital to small businesses and non-profit organizations of any size suffering substantial economic injury as a result of the Coronavirus (COVID-19), to help the businesses to meet financial obligations and operating expenses that could have been met had the disaster not occurred. This loan has interest of 3.75% and is not forgivable. The maturity of the loan is 30 years, installment payments including principal and interest of $288 monthly will begin 12 months from the date of the promissory note. On March 4, 2022, The FDS transferred its EIDL loan to BEC due to the dissolution of FDS. The SBA extended the deferment period to allow small businesses and not-for-profits that received EIDL funds do not have to begin payments on the loan until 30 months after the date of the note. Accordingly, the company began to make installment payments in the fourth quarter 2022.

 

As of September 30, 2026, the future minimum EIDL loan payments  to be paid by year are as follows:

 

Year Ending   Amount  
September 30, 2027   $ 1,358  
September 30, 2028     1,431  
September 30, 2029     1,484  
September 30, 2030     1,540  
September 30, 2031     1,598  
Thereafter     49,108  
Total   $ 56,519  

 

Commitments and Contingencies

 

From time to time, the Company may be a party to various legal actions arising in the ordinary course of business. The Company accrues costs associated with these matters when they become probable and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.

 

25

 

 

Commitment

 

Software Development Agreement

 

On September 1, 2026, the Company entered into a technology development agreement with Zhituo for the development of a practitioner-facing artificial intelligence and retrieval-augmented generation platform integrated with MediFlow. The contractual consideration consists of $1,000,000 in cash and 10,000,000 shares of the Company’s common stock.

 

As of September 30, 2026, the Company had paid $500,000, which was recorded as prepayment for software development (see Note 5). The remaining cash consideration of $500,000 is payable upon completion and acceptance of specified development milestones: $200,000 for architecture, detailed specifications and the initial prototype; $200,000 for the retrieval-augmented generation engine and practitioner AI agent; $50,000 for MediFlow integration and administrative functionality; and $50,000 upon final acceptance. The respective target milestone dates are October 23, November 13, November 30 and December 15, 2026. The Company may withhold the applicable milestone payment until material acceptance issues are corrected.

 

The 10,000,000 shares of common stock are earned and issuable only upon completion of all development obligations, delivery of all required deliverables and the Company’s written final acceptance, subject to applicable corporate and securities-law requirements. No shares are earned or vested upon execution of the agreement or completion of an interim milestone. The agreement specifies a contractual price of $0.10 per share, or $1,000,000 in aggregate; this contractual amount does not necessarily represent the fair value of the equity consideration for financial reporting purposes.

 

The Company may terminate the agreement for convenience upon 15 days’ written notice. Upon such termination, the Company is obligated to pay only for accepted milestones and, if it elects to receive partially completed work, the reasonable documented value of usable work in progress approved by the Company, subject to delivery of that work and the associated source code. No shares are earned or payable if the agreement is terminated before final acceptance.

 

Contingencies

 

On March 9, 2026, the Company was served with a summons and complaint filed by Stason Industrial Corporation (the “Plaintiff”). The complaint alleges breach of contract in connection with the Company’s early vacation of the Irvine facility and seeks damages of approximately $1.5 million.

 

As of September 30, 2026, the Company had accrued approximately $1.5 million related to this matter under lease liabilities. Management has evaluated the claim and determined that a loss is probable. While the Company intends to participate in the legal process, management believes the liability recorded as of September 30, 2026 representing the most likely outcome of this matter. Management does not believe it is reasonably possible that a loss materially in excess of the amount accrued will be incurred.

 

The complaint also asserts an additional cause of action alleging breach of a Statement of Work (“SOW”). The Plaintiff alleges that the Company failed to perform certain laboratory and pharmaceutical processing services and seeks recovery of alleged unreturned service payments as well as alleged lost revenues associated with a third-party agreement.

 

The Company is currently evaluating these allegations. The ultimate outcome of this claim is inherently uncertain, and management is presently unable to predict whether the Company will prevail. The Company intends to defend its position and may also engage in settlement discussions; however, the litigation remains in its early stages. As of September 30, 2026, management concluded that a loss related to the SOW claim was neither probable nor reasonably estimable; accordingly, no accrual has been recorded for this matter.

 

Off-Balance Sheet Arrangements

 

We have not entered into any financial guarantees or other commitments to guarantee the obligations of any third parties. We have not entered into any derivative contracts that are indexed to our shares and classified as shareholder’s equity or that are not reflected in our financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or research and development services with us.

 

26

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

As a smaller reporting company, as defined in 17 CFR § 229.10(f)(1), we are not required to provide the information requested by this Item.

 

Item 4. Controls and Procedures.

 

The Company’s Chief Executive Officer, Yin Yan, and Chief Financial Officer, William Sluss, are responsible for establishing and maintaining disclosure controls and procedures for the Company.

 

Evaluation of Disclosure Controls and Procedures

 

For purposes of this Item 4, the term disclosure controls and procedures means controls and other procedures of the Company (i) that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934, as amended (15 U.S.C. 78a et seq. and hereinafter the “Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC, and (ii) include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

  

On September 30, 2026, Ms. Yan and Mr. Sluss reviewed the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of the end of the period covered by this report and has concluded that the Company’s disclosure controls and procedures are not effective to ensure that material information relating to the Company is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. Ms. Yan and Mr. Sluss will continue to work on implementing controls and procedures to remedy this matter.

 

Report of Management

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (“ICFR”), as defined in Exchange Act Rule 13a-15. Our ICFR is designed to provide reasonable assurance to our management and board of directors regarding the preparation and fair presentation of published financial statements. Management conducted an assessment of our ICFR based on the framework and criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated Framework (2013). Based on the assessment, management concluded that, as of September 30, 2026, our ICFR were not effective at the reasonable assurance level based on those criteria. Management will continue to work to develop ICFR and controls over our reporting procedures.

 

Our independent public accountant has not conducted an audit of our controls and procedures regarding ICFR and therefore expresses no opinion with regards to the effectiveness or implementation of our controls and procedures with regards to ICFR.

 

Changes in Internal Controls over Financial Reporting

 

There were no changes in our ICFR identified in connection with our evaluation of these controls as of the end of the quarter ending on September 30, 2026, as covered by this report that has materially affected, or is reasonably likely to materially affect, our ICFR.

 

Inherent Limitations on Effectiveness of Controls 

 

The Company’s management does not expect that its disclosure controls or its ICFR will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting during the quarter ending on September 30, 2026 that have materially affected or are reasonably likely to materially affect, our internal control over financial reporting.

 

27

 

  

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

On or about February 27, 2026, Stason Industrial Corporation (“SIC”) and Stason Pharmaceuticals, Inc. (“SPI,” collectively “Stason”) filed a Complaint in the Superior Court of Orange County, in California (the “Complaint”), alleging that the Company breached its contract and lease obligations relating to a large commercial space previously utilized by the Company. The Company and ten (10) unidentified individuals are defendants of the case. The Complaint alleges that the Company breached rental payment obligations, and accrued late fees and other penalties pursuant to the operative agreements. The Complaint seeks $1,504,823.81 in damages as of January of 2026. The Company has retained legal counsel and is conducting discovery. The Company plans on vigorously defending the claims brought in the Complaint.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

Not applicable.

 

Item 6. Exhibits.

 

            Incorporated by reference
Exhibit   Exhibit Description   Filed
herewith
  Form   Period
ending
  Exhibit   Filing
date
31.1   Certification of the Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002   X                
32.1   Certification of the Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002   X                
101.INS   Inline XBRL Instance Document   X                
101.SCH   Inline XBRL Taxonomy Extension Schema Document.   X                
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.   X                
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.   X                
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.   X                
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.   X                
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).   X                

 

28

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

BIO ESSENCE CORP.  
   
/s/ Yin Yan  
By: Yin Yan  
Its: Chairman of the Board, Chief Executive Officer  
     
Date: November 12, 2026  
   
/s/ William E. Sluss  
By: William E. Sluss  
Its: Chief Financial Officer  
     
Dated:  November 12, 2026  

 

 

29

 

Keep reading